Tuesday , November 21 2017
Home / Therapies / GLP-1 Agonist Therapy Center (page 11)

GLP-1 Agonist Therapy Center

GLP-1 Diabetes Drug Treatment: GLP-1 (glucagon-like peptide 1 receptor agonists) are incretin mimetics which have several benefits for diabetes management. They suppress post-prandial glucagon release, delay stomach emptying, and increase insulin sensitivity. Significantly lower rates of hypoglycemia accompany GLP-1 therapy. This class also has the side effect of modest weight reduction and reduction of systolic blood pressure. GLP-1 receptor agonists are counter-indicated for patients with a history of pancreatitis.

GLP-1 Analogs, Appetite and Satiety


Cierra Harden PharmD Candidate 2013 LECOM School of Pharmacy, Bradenton Obesity is a major risk factor for the development of diabetes as well as predisposing individuals to hypertension and dyslipidemia. In the United States, 54.8% of persons with diabetes are obese, and 85.2% are overweight or obese1. All of these …

Read More »

Glycemic Efficacy of GLP-1 Receptor Agonists

What are the results after adding a GLP-1 receptor agonist to the treatment of type 2 patients after 30+ weeks of treatment?… During recent years, two strategies of incretin-based therapy [glucagon-like peptide-1 (GLP-1) receptor agonism and dipeptidyl peptidase-4 (DPP-4) inhibition] have entered the market for pharmacological management of type 2 …

Read More »

GLP-1 Agonist-based Therapies: An Emerging New Class of Antidiabetic Drug With Potential Cardioprotective Effects, Part 1


Melanie Sulistio, MD, Curtis Carothers, MD, Mandeep Mange, BS, Mike Lujan, BS, Rene Ofiveros, MD, and Robert Chilton, DO Cardiovascular disease is a leading cause of death in the United States and across the world, and better therapies are constantly being sought to improve patient outcomes. Recent studies have brought …

Read More »